SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Alterity Therapeutics Limited PRNAF OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Alterity Therapeutics Limited (PRNAF) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $5M, +4.8%/yr average growth. Net income is $12M (loss), growing at -3.2%/yr. Net profit margin is -223.4% (negative). Gross margin is 97.7% (-1.2 pp trend).

Balance sheet: total debt is $155,457 against $42M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 12.98 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $46M.

Analyst outlook: 1 / 1 analysts rate PRNAF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

PRNAF SharesGrow Score Overview

57/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 30/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PRNAF

No analyst coverage available for this stock.

PRNAF: +4.8%/yr revenue is, -3.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet PRNAF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 12.98 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

PRNAF: Gross margin is 97.7% (-1.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate PRNAF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

PRNAF: Net profit margin is -223.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0002-0.0139

Volume10K

Avg Volume (30D)9.49K

Market Cap$11.96M

Beta (1Y)-0.07

Share Statistics

EPS (TTM)0.00

Shares Outstanding$6.4B

IPO Date2012-09-25

Employees10

CEODavid A. Stamler

Financial Highlights & Ratios

Revenue (TTM)$5.44M

Gross Profit$5.31M

EBITDA$-14.63M

Net Income$-12.15M

Operating Income$-14.57M

Total Cash$40.66M

Total Debt$155.46K

Net Debt$-33M

Total Assets$46.03M

Price / Earnings (P/E)-0.6

Price / Sales (P/S)2.2

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryAU

ExchangeOther OTC

CurrencyUSD

ISINAU0000043945

Price Chart

PRNAF

Alterity Therapeutics Limited ↗ · Other OTC

Healthcare • Biotechnology

0.00 52WK RANGE 0.01

People Also View

Madrigal Pharmaceuticals, Inc.

TG Therapeutics, Inc.

Viking Therapeutics, Inc.

Greenwich LifeSciences, Inc.

Northwest Biotherapeutics, Inc.

Gracell Biotechnologies Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message